Loading...

MARKSANS Marksans Pharma Ltd Earnings Reports Announcement

Mrks

MRKS

Marksans Pharma Ltd

(MARKSANS)

2026 Announcement

Newspaper publication

Annual Secretarial Compliance

Final dividend recommendation

Q4 FY26 results

Investor Presentation

Final dividend declared

Audited Financial Results

Conference Call

Board Meeting for results

Regulatory Compliance

Regulatory Compliance

Regulatory disclosure

Regulatory Compliance

Conference participation

Earnings Call Transcript

Audio Recording

Unaudited Financial Results

Unaudited results

Investor Presentation

Unaudited Financial Results

Board meeting outcome

Geographic Expansion

Earnings conference call

Regulatory Compliance

Board meeting for results

Trading window closure

Analyst meet transcript

Marketing Authorization

Regulatory approval

Newspaper advertisement

Audio recording release

Unaudited Results

Investor Presentation

Unaudited results

Board Meeting Outcome

Vigilance Awareness Week

FDA Inspection Success

New Product Approval

Saksham Niveshak Campaign

Investor Call Scheduled

ESG Score Update

Marketing Authorization

Compliance Certificate

Credit Rating Upgrade

100 Day Campaign

ESOP Grant Announced

Marketing Authorization Gra...

100 Day Campaign

IEPF Publication

Saksham Niveshak Campaign

Saksham Niveshak Campaign

Earnings Call Transcript

Marketing Authorization Gra...

Investor Meet Audio

Financial Results Published

Q1 FY26 Results

Investor Presentation

AGM Voting Results

Investor Meet Scheduled

AGM Notice Update

Management Reappointment

AGM Notice Published

AGM Notice Published

AGM Notice Published

Secretarial Auditor Appointed

Compliance Certificate

USFDA Inspection Report

Product Authorization

Marketing Authorization Rec...

Annual Compliance Report

Q4 FY25 Earnings

Financial Results Announced

Investor Meet Outcome

Director Appointment

Record Earnings Results

Investor Presentation

New Product Authorization

Marketing Authorization

Conference Call Scheduled

FDA Inspection Notice

Compliance Certificate

Director Cessation

Investor Conference

Product Authorization

Credit Rating Upgrade

New Product Authorization

New Product Approval

Earnings Call Transcript

Investor Call Update

Financial Results Q3

No Deviation Found

Strong Q3 Results

Investor Presentation

Investor Meet Scheduled

SEBI Compliance Certificate

Investor Meet Notice

Q2 FY25 Earnings

FDA Approval Received

Investor Meet Recording

Financial Results Update

No Fund Deviation

Financial Results Q2

Investor Presentation

Earnings Call Scheduled

Credit Rating Update

SEBI Compliance Certificate

Investor Meeting

AGM Announcement

Q1 FY25 Earnings Update

Product Authorization

FDA Inspection Success

Investor Meeting Update

Financial Results

No Deviation Report

Director Re-Appointment

Strong Q1 Performance

Investor Presentation

Marketing Authorization Rec...

Newspaper Publication

Certificate Submission

Re-Appointment Notice

Marketing Authorization

Investor Meeting

Deviation Confirmation

Financial Results

Investor Presentation

Marketing Authorization for...

Annual Compliance Report Su...

Conference Analyst Meet

FDA Inspection Observations

Certificate Submission

Compliance Certificate

Compliance Certificate Subm...

Transcript Release

Investor Meeting

Newspaper Advertisement

No Deviation in Use of Funds

Financial Results

Earnings Presentation

Conference Call Scheduled

Certificate Submission

Credit Rating Upgrade

Advertisement of Financial ...

Investor Conferences

Confirmation of No Deviatio...

Q2 and H1 FY24 Financial Re...

Earnings Presentation

Marketing Authorization Rec...

US FDA Inspection

Conference Call Scheduled

Inspection success

Credit Rating Reaffirmation

Certificate Submission

Amendment to Articles of As...

Investor Conference

Management Changes

Transcript release

Disposals and divestitures

Conference Call

Financial Statements

Rights Offerings

Financial Statements

Financial Statements

Financial Statements

Post-Marketing Inspection

Annual General Meeting

Conference Call

Publication of financial re...

Related Party Transactions

Preferential issue of conve...

Appointment of Independent ...

Investor Meetings

Management Changes

Financial Statements

External Links:

Data:

Marksans Pharma reports FY26 revenue of ₹3,033 crore, EBITDA of ₹601 crore, and PAT ₹420 crore, with strong Q4 growth and expansion across markets; cash balance ~₹990 crore.

AI Assistant

Marksans Pharma Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.